Artineh Hayrapetian 1Mark D GirgisJane YanagawaSamuel W FrenchHeinrich R Schelbert 1Martin S Auerbach 1Johannes CzerninJeremie Calais

Abstract: A 71-year-old man underwent 18F-FDG and 68Ga-FAPI-46 PET/CT for initial staging prior to surgery of a squamous cell carcinoma of the lower esophagus under the prospective study NCT04147494. Both scans showed increased uptake in the mid and distal esophagus without evidence of metastatic disease. A soft tissue right infrascapular mass with mild 18F-FDG and moderate 68Ga-FAPI-46 uptake was incidentally found. The patient underwent robotic-assisted Ivor-Lewis esophagectomy and excision of the right infrascapular mass. Histopathology of the right chest wall mass confirmed the diagnosis of elastofibroma.

Conflict of interest statement

Conflicts of interest and sources of funding: J. Calais is a consultant for Progenics Radiopharmaceuticals, Radiomedix, Blue Earth Diagnostics, Janssen Pharmaceuticals, and Curium Pharma. Consulting activities are outside of the submitted work. He is the recipient of grants from the ERF-SNMMI (2019–2021 Molecular Imaging Research Grant for Junior Academic Faculty), the Philippe Foundation Inc (New York), and the ARC Foundation (France) (International Mobility Award SAE20160604150). J. Czernin is a founder and board member and holds equity in Sofie Biosciences and Trethera Therapeutics. Intellectual property patented by the University of California is licensed to Sofie Biosciences and Trethera Therapeutics. J. Czernin serves on the medical advisory board of Actinium and is a member of the VISION trial steering committee, a clinical trial sponsored by Endocyte. J. Czernin is the recipient of a grant from the Prostate Cancer Foundation (2017 and 2019 Challenge Awards, 17CHAL02; 19CHAL02) and from the Johnson Comprehensive Cancer Center NIHNCI Cancer Center Support Grant (P30 CA016042). The other authors have none declared.


  1. From the Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology.